Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1468-3083.2008.02671.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anaplastic Large B-Cell Lymphoma: Cutaneous Presentations.
Cureus
October 2024
Department of Dermatology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.
Article Synopsis
- Anaplastic large cell lymphoma (ALCL) is a rare T-cell lymphoma marked by the presence of CD30 and can often be mistaken for other conditions due to its vague symptoms.
- A 10-year-old girl initially treated for a bacterial infection was later diagnosed with ALK-negative ALCL after a biopsy revealed the disease, with additional imaging showing lung involvement and a Murphy stage II classification.
- The case highlights the necessity of early biopsy and molecular testing when initial treatments don't work, emphasizing that prompt diagnosis and thorough examinations can significantly enhance treatment success and patient prognosis.
Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.
Patients And Methods: Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy.
[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development].
Gan To Kagaku Ryoho
July 2024
Dept. of Hematology and Oncology, University of Fukui.
Article Synopsis
- * In Japan, four ADCs are approved: gemtuzumab ozogamicin for acute myeloid leukemia, brentuximab vedotin for various types of Hodgkin's and T-cell lymphomas (showing improved progression-free survival), inotuzumab ozogamicin for B-cell acute lymphoblastic leukemia (with higher remission rates), and polatuzumab vedotin for diffuse large B-cell lymphoma (which also improves outcomes when used with standard chemotherapy).
- * Despite their
Cutaneous Lymphoma in a Tertiary Skin Hospital and Referral Centre in Nepal.
J Nepal Health Res Counc
June 2024
DI Skin Hospital and Referral Centre Private Ltd, Bansbari, Budanilkantha, Kathmandu, Nepal.
Article Synopsis
- Primary cutaneous lymphomas are rare skin cancers that do not have lymphomas outside the skin when they are diagnosed, and there is currently no data on this condition in Nepal.
- This study looked at 15 cases of cutaneous lymphomas diagnosed at a hospital in Kathmandu, with patients having a median age of 45 years and more males than females.
- The findings showed that 87% of the lymphomas were T-cell types, with mycosis fungoides being the most common subtype, while only 13% were B-cell lymphomas.
Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV-CHP?
Lancet Haematol
September 2024
Hematology Department, Lyon Sud Hospital, Hospices Civils de Lyon, 69495 Piere Bénite, France; Lymphoma Immuno-Biology Research Unit, Inserm U1111, CIRI, Lyon, France. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!